Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Shares Sold by Atticus Wealth Management LLC

Atticus Wealth Management LLC reduced its position in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 18.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,512 shares of the company’s stock after selling 12,812 shares during the period. Atticus Wealth Management LLC owned approximately 0.07% of Tenaya Therapeutics worth $296,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. HighPoint Advisor Group LLC purchased a new position in Tenaya Therapeutics in the 4th quarter worth about $228,000. NEOS Investment Management LLC purchased a new position in Tenaya Therapeutics in the 4th quarter worth about $201,000. Bailard Inc. acquired a new stake in Tenaya Therapeutics during the 4th quarter worth about $107,000. Cornercap Investment Counsel Inc. boosted its position in Tenaya Therapeutics by 136.2% during the 4th quarter. Cornercap Investment Counsel Inc. now owns 81,255 shares of the company’s stock worth $263,000 after acquiring an additional 46,847 shares during the period. Finally, Redwood Wealth Management Group LLC boosted its position in Tenaya Therapeutics by 38.0% during the 4th quarter. Redwood Wealth Management Group LLC now owns 16,350 shares of the company’s stock worth $53,000 after acquiring an additional 4,500 shares during the period. Hedge funds and other institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Stock Performance

Shares of Tenaya Therapeutics stock traded up $0.16 during trading on Friday, hitting $3.10. 1,869,736 shares of the stock traded hands, compared to its average volume of 364,810. The stock has a market cap of $243.41 million, a P/E ratio of -1.89 and a beta of 2.52. Tenaya Therapeutics, Inc. has a twelve month low of $1.66 and a twelve month high of $7.01. The company has a fifty day moving average price of $3.99 and a two-hundred day moving average price of $4.29.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.03. On average, equities research analysts expect that Tenaya Therapeutics, Inc. will post -1.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. William Blair assumed coverage on Tenaya Therapeutics in a research report on Monday, June 10th. They set an “outperform” rating for the company. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Wednesday, May 15th. Canaccord Genuity Group decreased their price objective on Tenaya Therapeutics from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, May 16th. Finally, Chardan Capital restated a “buy” rating and set a $20.00 price objective on shares of Tenaya Therapeutics in a research report on Thursday, March 21st. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $15.00.

Tenaya Therapeutics Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.